Mar 01, 2023 / 01:00PM GMT
Operator
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Tyra Biosciences Conference Call to discuss the expansion of the development of TYRA-300. As a reminder, this conference call is being recorded.
Now I would like to turn the call over to Amy Conrad from Investor Relations. Please go ahead.
Amy Conrad - Tyra Biosciences, Inc. - Investor Contact
Thank you, Rob. Good morning, everyone, and thank you for joining us. With me today from Tyra are Todd Harris, Chief Executive Officer; Ron Swanson, Chief Scientific Officer; and Hiroomi Tada, Chief Medical Officer. Also on today's call are Dr. Michael Bober, Medical Director of the Skeletal Dysplasia Program at Nemours Children's Hospital, Delaware; and Dr. Laurence Legeai-Mallet from the Imagine Institute in Paris, France.
Before we begin, I would like to remind you that on today's call, we will be making forward-looking statements concerning Tyra's future expectations, plans, prospects, strategy and performance, which constitute forward-looking statements for the purposes of
Tyra Biosciences Inc To Discuss Expansion of TYRA-300 Development Call Transcript
Mar 01, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers